NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»18/12/2009 [Industry news]
Alvogen launches Asia operations

Alvogen China will also serve as a global sourcing unit for active pharmaceutical ingredients and finished products that will be used throughout the company’s regional business units that encompass North America, Europe and Asia.

 
Alvogen, a US-based pharmaceutical company, has established operations in Asia and has opened an office in Shanghai, China that will lead efforts to commercialise the company products in the country. The Chinese market is said to represent a strategic gateway for future business development in Asia as the company aims to solidify its presence in the region. Alvogen China will also serve as a global sourcing unit for active pharmaceutical ingredients and finished products that will be used throughout the company’s regional business units that encompass North America, Europe and Asia. “We see great opportunities for our business in Asia, and the creation of Alvogen China is integral to our development strategy. Through registration of our own products, portfolio acquisitions and strategic partnerships, we aim to build a strong presence in the market with a targeted product offering,” said Mr Robert Wessman, Executive Chairman of Alvogen. “We are committed to identifying new alliances in China that will further strengthen our development, manufacturing and sourcing capabilities.” Dr Qin Maximilian Lue, who is the primary shareholder of Shanghai-based Mephax Holdings, will become the managing director of Alvogen China, and will lead a newly recruited team with extensive experience. Dr Lue has over 20 years of experience in the global medical and pharmaceutical market. Alvogen believes that the Chinese market will experience strong growth in the coming years and will play a central role in the company’s international expansion. “Within the next five years we aim to be one of the strongest pharmaceuticals companies in China, recognised for our reputation of high quality products and services,” said Mr Doug Drysdale, CEO, Alvogen. “It is our vision to build a leaner and more flexible multinational operation that overcomes the challenges of the traditional generics business model.”

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.